Announcements

25 July 2025
Meet Us at the 37th European Congress of Pathology (ECP 2025), 6–10 September 2025, Vienna, Austria


Conference:
37th European Congress of Pathology (ECP 2025)
Date: 6–10 September 2025
Location: Vienna, Austria

The European Society of Pathology (ESP) and the Austrian Society for Clinical Pathology and Molecular Pathology (ÖGPath) invite you to the 37th European Congress of Pathology (ECP). The conference will take place in the Austria Center Vienna (ACV), in the heart of Vienna, 6–10 September 2025. The ECP has grown to become the world’s largest congress in Pathology with a dynamic scope, attracting over 5000 colleagues from all over the world. Over these five days in September, pathologists, clinicians, molecular biologists, geneticists, bioinformaticians, IT experts, as well as our industry partners, will gather for the ECP 2025 and make Vienna the world capital of Pathology. You can view the detailed conference topics at https://www.espcongress.org/topics/.

We will be attending the 37th European Congress of Pathology (ECP 2025), and we welcome researchers from different backgrounds to visit and share their latest ideas with us.

The following open access journals will be represented:

If you plan to attend this conference, please contact us online. Our delegates look forward to meeting you in person at booth #13 (Hall X5) and answering any questions that you may have. For more information about the conference, please visit the following website: https://www.espcongress.org/welcome-address/.

16 July 2025
Meet Us at the ESMO Congress 2025, 17–21 October 2025, Berlin, Germany


The ESMO Congress is a significant global oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. ESMO 2025 aims to converge groundbreaking discoveries, innovative treatments and collaborative approaches to shape the future of cancer care. This event provides the opportunity to learn from internationally renowned experts, engage in thought-provoking discussions and connect with fellow oncology professionals who are advancing diagnosis, treatment and survivorship in this field.

The following MDPI journals will be represented at this conference:

If you are planning to attend the above conference, please feel free to start an online conversation with us. Our delegates look forward to meeting you in person at booth #P2007 and answering any questions that you may have.

For more information about this conference, please visit the following website: https://www.esmo.org/meeting-calendar/esmo-congress-2025.

7 July 2025
Meet Us at the European Academy of Dermatology & Venereology (EADV) 2025, 17–20 September 2025, Paris, France


Conference: European Academy of Dermatology & Venereology (EADV) 2025
Date: 17–20 September 2025
Location: Paris, France 

MDPI will attend the European Academy of Dermatology & Venereology (EADV) 2025, which will be held from 17 to 20 September 2025, as an exhibitor (booth position—A24). We welcome researchers from various backgrounds to visit our booth and share their latest ideas with us.

It is with great pride and anticipation that we welcome you to the EADV Congress 2025, set against the vibrant backdrop of Paris—a city synonymous with elegance, culture, and innovation. As we gather at the Paris Convention Centre, we unite once again to celebrate the very best in dermatology and venereology.

This year’s Congress promises to be our most dynamic yet. With over 180 scientific sessions, 600+ expert speakers, 25+ dedicated subspecialty tracks, and 10 powerful plenary lectures, our programme reflects the incredible depth and breadth of our field. We are especially excited to host abstract-based free communications, late-breaking research highlights, and a residents-targeted session, ensuring opportunities for every level of expertise and interest.

The following open access journals will be represented at the conference:

If you are planning to attend this conference, please do not hesitate to start an online conversation with us. Our delegates look forward to meeting you in person at the booth and answering any questions that you may have.

4 July 2025
MDPI’s Newly Launched Journals in June 2025

Six new journals covering a range of subjects launched their inaugural issues in June 2025. We are excited to be able to share with you the newest research rooted in the value of open access. We are pleased to present the latest research and to make it accessible to all.

We extend our sincere thanks to all the Editorial Board Members for their commitment and expertise. Each journal is dedicated to upholding strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.

Please feel free to browse and discover more about the new journals below.

Journal Founding Editor-in-Chief Journal Topics (Selected)
Prof. Dr. Chang-Pu Sun,
China Academy of Engineering Physics, Beijing, China; Computational Science Research Center, China
Editorial | View inaugural issue
quantum information and phenomena; condensed matter physics and statistical physics; atomic, molecular, and optical physics; computational physics and mathematical methods
View journal scope | Submit an article
Prof. Dr. Hualiang Lin,
Sun Yat-sen University, China;
Prof. Dr. Jose L. Domingo,
Universitat Rovira i Virgili, Spain
Editorial | View inaugural issue
green and organic food; green infrastructures; green exercise; environmental impact of the healthcare sector; effects of climate change on human health |
View journal scope | Submit an article
Prof. Dr. Francesco Veglio,
University of L’Aquila, Italy
Editorial | View inaugural issue
ultra-pure substances; water purification; air purification; gas purification; inorganic chemical purification; purification technologies
View journal scope | Submit an article
Prof. Dr. Junxing Zheng,
Huazhong University of Science and Technology, China
Editorial | View inaugural issue
computer-aided design and engineering; artificial intelligence and machine learning; building information modeling (BIM) and digital twins; robotics and automation in construction; smart sensors and Internet of Things (IoT); intelligent control systems and facilities management
View journal scope | Submit an article
Prof. Dr. Assunta Di Vaio,
University of Naples Parthenope, Italy
Editorial | View inaugural issue
sustainability, managerial, and biodiversity accounting; carbon management accounting; corporate social responsibility; artificial intelligence and disclosure
View journal scope | Submit an article
Prof. Dr. Changjun Liu,
Sichuan University, China
Editorial | View inaugural issue
bioeffects of electromagnetic waves; electromagnetic science and engineering; microwave, millimeter-wave, and terahertz technologies; metamaterials and metasurfaces; communication, sensing, and networks; energy, power, and sustainable applications; quantum and emerging technologies; artificial intelligence and advanced fabrication
View journal scope | Submit an article
We wish to thank everyone who has supported the development of open access publishing. If you are interested in launching a new open access journal with us, you are welcome to send an application here.

2 July 2025
Meet Us at the 8th International Conference on Prevention & Infection Control, 16–19 September 2025, Geneva, Switzerland


Conference:
The 8th International Conference on Prevention & Infection Control
Date: 16–19 September 2025
Location: Geneva, Switzerland

MDPI will be attending the 8th International Conference on Prevention & Infection Control (ICPIC), which will be held between 16 and 19 September 2025, as an exhibitor. We welcome researchers from various backgrounds to visit our booth and share their latest ideas with us.

ICPIC stands as the premier gathering for the global infection prevention and control (IPC) community, dedicated to advancing the field through cutting-edge research, innovative solutions, and the exchange of invaluable experiences. Our mission remains steadfast: to prevent healthcare-associated infections and control antimicrobial resistance, in addition to improving patient and healthcare worker safety worldwide. This year, our conference will delve into an array of crucial topics, including hand hygiene, artificial intelligence (AI)/machine learning, antibiotic stewardship, surgical site infection prevention, new techniques and approaches in environmental hygiene, environmental responsibility and eco-friendly solutions in IPC, and diagnostic as well as clinical microbiology challenges for IPC.

We eagerly anticipate your participation at the conference and look forward to welcoming you to Geneva. Please mark your calendars and prepare for an inspiring and enriching event.

The following MDPI journals will be represented at the conference:

If you are planning to attend this conference, please do not hesitate to start an online conversation with us. Our delegates look forward to meeting you in person at the booth and answering any questions that you may have. For more information, please visit https://conference.icpic.com/.

2 July 2025
MDPI INSIGHTS: The CEO's Letter #24 - 2024 Impact Factor & CiteScore, MDPI Summits France & USA, Tu Youyou Award

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

MDPI’s 2024 Impact Factor Highlights

For those of our readers who are new to academic publishing, you may have heard some news in June around the Impact Factor release. Every year, typically in June, Clarivate releases its annual Journal Citation Reports (JCR), which include Journal Impact Factors (JIF). This metric is widely used in academic publishing to reflect the average number of citations received by recent articles in each journal.

While Impact Factor is just one of many indicators of journal influence, it remains a major milestone for authors, editors, and publishers. It’s used to assess journal visibility, researcher recognition, and scholarly reach. Throughout our international meetings and events, it’s clear that the Impact Factor is something many of our authors and editorial board members care about, as it can influence where they choose to submit an article and the funding they receive for their research.

“These results reflect the trust that the scholarly community places in MDPI”

MDPI’s 2024 Impact Factor Highlights

  • 298 MDPI journals received a Journal Impact Factor.
  • 60 journals earned their first-ever Impact Factor
    • To put this in perspective: MDPI’s 60 new journal acceptances into the Web of Science was the second highest number of any publisher in 2024, behind Elsevier and ahead of Springer Nature. Our 87% acceptance rate for journals submitted to Web of Science shows the strength of our editorial process and our proven ability to develop journals aligned with Clarivate’s 24 evaluation criteria.
    • Notably, Textiles, Mathematics, International Journal of Neonatal Screening, Smart Cities, Systems, and Pharmaceutics ranked in the top 10% in their respective categories, highlighting their growing influence and prestige within their academic fields. This shows that high-quality indexing goes beyond visibility; it upholds credibility and trust.
  • 193 MDPI journals are now ranked in the top 50% (Q1/Q2) of their subject categories.
    • What does this mean, and why is it important? Journals are ranked by quartiles within their field, based on their Impact Factor. Q1 represents the top 25% of journals in their category, Q2 the next 25%, and so on. Being in Q1 or Q2 shows that a journal is performing well relative to other journals in its category. Authors and institutions often look at quartile rankings when choosing where to publish – it’s an important indicator of visibility and recognition, within its respective category.
  • 116 of our previously ranked journals increased their Impact Factor.
  • 14 MDPI journals achieved an Impact Factor of 5.0 or higher, suggesting a high degree of influence and visibility.

These results reflect our staff's hard work: from our editorial and production teams to our indexing, communications, and data teams, and beyond. This also reflects the trust that the scholarly community places in MDPI, reinforcing the message that when researchers publish with MDPI, they publish with impact.

Open Access with Impact

As the leading fully open access publisher, our journals have received a total of 18.4 million citations in the Web of Science by the end of 2024, reflecting the growing reach and engagement of research published with MDPI. We are committed to making scientific research freely accessible to everyone, everywhere. With the support of more than 4.2 million contributing authors, we’re proud to support the global shift toward open access.

Further Reading

If you’d like to better understand how journals get indexed and why Impact Factors matter, please read this recent interview with Dr. Constanze Schelhorn (Head of Indexing). It gives you a behind-the-scenes look at the role our indexing team plays in supporting journal indexing and visibility.

You can also read our official news announcement shared last week: MDPI Journals in the 2024 Journal Citation Reports.

Thank you to everyone, from our authors and reviewers to our editors and internal teams, who contributed to the progress of our journal indexing in 2024. We’re continuing to build journals that are recognized and trusted across disciplines.

Impactful Research

MDPI Journals See Continued Growth in 2024 CiteScore Results

Continuing our indexing updates, I’m pleased to share that MDPI has achieved strong results in the latest CiteScore metrics, released on 5 June by Scopus. These results reflect the collective efforts of our editors, reviewers, authors, and internal teams, with their dedication to quality and visibility in scientific publishing. You can read the full announcement here.

2024 Highlights:

  • 322 MDPI journals received a CiteScore (up from 274 last year).
  • 283 journals (88%) are ranked in Q1 or Q2 of their subject categories.
  • 237 journals (85%) saw an increase in their CiteScore compared to last year.
  • 48 journals received a CiteScore for the first time.
  • 39 journals are now placed in the top 10% of their subject areas.

“This growth highlights our commitment to supporting open, trusted science”

What is CiteScore and how is it measured?

CiteScore metrics are developed by Elsevier as an alternative to the Impact Factor. They measure the citation impact of journals and can be accessed freely on Scopus. The metric represents the yearly average number of citations to recent articles published in a journal. If you’re interested in learning more about citation metrics and how we use them, check out this blog post.

Why is this important?

These results show the growing recognition for, and impact of, MDPI journals across disciplines. CiteScore rankings help researchers, institutions, and funders assess where high-quality work is being published. This growth improves our journals’ positioning in the publishing landscape and highlights our commitment to supporting open, trusted science.

Inside MDPI

Highlights from the MDPI USA Summit in Boston (5–6 June)

With several Summits already behind us, I think this is a good time to reflect on the purpose of these Summits.

Why do we organize MDPI Summits?

These one-and-a-half-day, invite-only gatherings are designed to improve our relationships with Chief Editors who lead our journals and are respected voices in their fields. The Summits aim to:

  1. Share MDPI’s values, achievements, editorial practices, and local market collaborations.
  2. Collect feedback on MDPI operations and journal practices.
  3. Empower Chief Editors to confidently represent MDPI beyond the Summit.

While Chief Editors know their journals well, these events help them better understand MDPI. We want them to be ambassadors for our brand. The aim is for them to walk away informed, engaged, and equipped to share positively about MDPI.

About the Boston Summit

Held on 5–6 June, our first USA Summit gathered over 25 Chief Editors to learn more about MDPI’s activities and collaborations in the USA. The program included presentations, Q&A, and a panel discussion.

Agenda Highlights:

Moderated by Summer Huggard (Operations Manager [Toronto], MDPI), the program featured:

  • MDPI Overview and USA Collaboration – Stefan Tochev (CEO, MDPI)
  • AI in Publishing and MDPI's Actions – Feichi Lu (Junior Data Scientist, MDPI)
  • MDPI Editorial Process and Research Integrity – Dr. Giulia Stefenelli (Scientific Communications Lead, MDPI)
  • Panel Discussion – Stefan, Feichi, Giulia, Claudia
  • Society Partnerships – Dr. Clàudia Aunós (Society Partnerships Senior Manager, MDPI)
  • Voice of the Customer and Closing Remarks – Stefan Tochev (CEO, MDPI)

MDPI & the USA: Facts and Figures

  • With over 216,000 publications, the USA is MDPI’s second-largest contributor after China.
  • In 2024, the USA ranked 2nd in total submissions and 2nd in total MDPI publications, with more than 28,200 publications.
  • As of 2020, the cumulative number of authors from the USA until April 2025 was 352,099.
  • As at April 2025, there are more than 12,035 active Editorial Board Members (EBMs) from the USA, with 55% having an H-index over 26.
  • Among them, 96 serve as Editors-in-Chief (EiC) and 218 as section-Editors-in-Chief (SEiC)
  • MDPI has more than 920 Institutional Open Access Program agreements worldwide, with over 130 from the USA.

A special thanks to our Toronto team, and everyone who worked behind the scenes to make this event run smoothly.

Coming Together for Science

Highlights from the MDPI France Summit in Paris (12–13 June)

We completed our first MDPI France Summit in Paris last week, and it was a special event. Attendees were engaged from beginning to end, remaining after hours to network and collaborate.

Why a France Summit?

We chose to host a France Summit in view of the recent challenges MDPI has faced with the National Centre for Scientific Research (CNRS). What we took away from the event is that our authors and editors very much appreciate and enjoy working with us, but we need to address the concerns raised by CNRS, around Article Processing Charges (APCs) and the funding of gold open access publications.

“Our authors and editors very much enjoy working with us”

Some of the claims made in the June 2023 interview with Alain Schuhl, the Deputy CEO for Science at the CNRS, are simply not factual. For example, they state that MDPI’s “average APC charges per article are now around the same as Springer Nature’s.” Here is the relevant passage, reproduced verbatim:

This is not accurate.

A recent preprint analysing APC data from Elsevier, Springer Nature, Wiley, PLOS, MDPI, and Frontiers (2019–2023) shows that MDPI’s average APCs remain significantly lower than those of Springer Nature and several other major publishers.

The MDPI Summits are part of our outreach and communication efforts to address misconceptions and clarify MDPI’s position as one of the most accessible and affordable major gold open access publishers in the world.

Summit Overview

Held on 12–13 June, the France Summit gathered over 20 Chief Editors to learn more about MDPI’s activities and collaborations in France. Many of these editors are influential in their institutions and professional societies. Several also have connections to CNRS, which makes this an important opportunity to clarify how we operate and build trust through open and transparent communication and hopefully turn our editors into informed advocates of MDPI.

Summit Feedback

The feedback has been very positive, with most attendees completing the post-event survey and all rating the experience as Excellent or Good. A few highlights:

  • “The whole thing was highly professional and, above all, provided quantified details that will allow us to better answer questions surrounding MDPI.”
  • “The summit was an opportunity to meet personally various people directly engaged in the organization and policies of MDPI, which made it possible to clarify some important points concerning publishing with MDPI.”
  • “Very well organized! A great opportunity to see all French MDPI partners and editors.”

Program Highlights:

Moderated by Miruna Adelina Nicolcioiu (Senior Conference Producer), the program featured:

  • MDPI Overview and France Collaboration – Stefan Tochev (CEO)
  • MDPI Editorial Process and Peer-Review Quality – Dr. Marta Colomer (Public Affairs Specialist)
  • Institutional Partnerships and Open Access Funding Models – Becky Castellon (Institutional Partnerships Manager)
  • AI in Publishing and MDPI's Actions – Daniele Raimondi (Data Scientist)
  • Publication Ethics: Global Trends – Diana Cristina Apodaritei (Research Integrity Specialist)
  • Closing Remarks – Stefan Tochev
  • Panel Discussion – Diana, Becky, Prof. Dr. Patrick Da Cost, and Stefan

MDPI & France: Facts and Figures

  • With over 51,000 publications, France is MDPI's tenth-largest contributor, and fifth largest among EU countries after Italy, Spain, Germany, and Poland.
  • As of 2020, the cumulative number of authors from France until April 2025 was 87,592.
  • As at April 2025, there are more than 2,800 active Editorial Board Members (EBMs) from France, with 59% having an H-index over 26.
  • Among them, 22 serve as Editors-in-Chief (EiC) and 61 as section-Editors-in-Chief (SEiC)
  • In 2024, IJMS, JCM, and Molecules were the top three MDPI journals in terms of submissions from French-affiliated authors.

Special thanks to our colleagues from Romanian offices for organizing this successful event.

Closing Thoughts

Richard DiMarchi and Rolf Müller Share the 2024 Tu Youyou Award

As we wrap up this month’s newsletter, I’d like to take a moment to recognize the winners of the 2024 Tu Youyou Award, presented by our journal Molecules. I am pleased to share that the 2024 Tu Youyou Award has been conferred upon Richard DiMarchi and Rolf Müller, in recognition of their significant contributions to natural products chemistry and medicinal chemistry.

I invite you to read the editorial co-authored by the Tu Youyou Award Committee, which highlights the significance of the award and the remarkable impact of the recipients’ research.

A sincere thank-you to the 2024 Award Committee for their dedication and selection process, and congratulations once again to this year’s honourees. Your work exemplifies the kind of research MDPI is proud to support and amplify.

About the Tu Youyou Award
The 2024 Tu Youyou Award includes a total monetary prize of 100,000 Swiss Francs and a medal for each recipient. Established in 2016 to honour the pioneering spirit of Nobel laureate Tu Youyou, the Tu Youyou Award is an international award recognizing exceptional scholars dedicated to the fields of natural products chemistry and medicinal chemistry.

For further information about the award and the winners, please visit the Tu Youyou Award website.

Stefan Tochev
Chief Executive Officer
MDPI AG

27 June 2025
The Editor-in-Chief’s Letter—Diagnostics Receives an Updated Impact Factor of 3.3

Dear Editorial Board Members, Guest Editors, Authors, and Reviewers,

It is with great pleasure that I share the news that Diagnostics (ISSN: 2075-4418) has received an increased Impact Factor of 3.3 for 2024 (JCR Q1, 57/332). Diagnostics also received an increased CiteScore of 5.9 (marking the fifth consecutive year of growth). This continued growth reflects your invaluable contributions, unwavering support, and commitment to scientific excellence.

I would like to extend my sincere gratitude to each of you for your dedication, insightful reviews, and high-quality submissions. Together, we have strengthened the journal’s visibility, scientific impact, and community.

I look forward to building further on this momentum and to our continued collaboration in the coming years.

Best regards,
Professor Andreas Kjaer
Editor-in-Chief, Diagnostics

25 June 2025
Diagnostics Receives an Increased Impact Factor of 3.3


We are pleased to share that the Diagnostics (ISSN: 2075-4418) was awarded an increased Impact Factor of 3.3 in the 2024 Journal Citation Reports™ released by Clarivate™ in June 2025. Diagnostics ranks in Q1 (57 among 332 titles) in the “Medicine, General and Internal” category. 

The 2024 Journal Impact Factor is calculated by dividing the number of citations received in 2024 to all publications in the journal from 2022 and 2023 by the total number of citable publications from those same years. 

To learn more, visit our journal statistics website for detailed metrics or check out our news article for general information. 

The support and dedication of all the editors, reviewers, authors, and readers are an integral part of the journal’s performance. We would like to take this opportunity to thank all of you who have contributed to the journal.

25 June 2025
Diagnostics Receives an Increased CiteScore of 5.9


We are pleased to share that Diagnostics (ISSN: 2075-4418) has received an increased CiteScore of 5.9 in June 2025. The CiteScore ranks the journal 47 out of 171 titles (Q2) in the “Internal Medicine” category, and 45 out of 121 titles (Q2) in the “Clinical Biochemistry” category, an impressive achievement for a journal running in Volume 15.

You can find more statistics on our website

The current CiteScores measure the average number of citations within a journal over a four-year window (2021–2024). The Scopus database provides a comprehensive suite of metrics that support informed publishing strategies, research evaluation and enable benchmarking of journal performance. 

This achievement reflects the collective efforts of our authors, reviewers, and editors. Together we will continue to track the progress of Diagnostics and its growing impact in medical diagnosis research.

12 June 2025
International Albinism Awareness Day—“Demanding Our Rights: Protect Our Skin, Preserve Our Lives”, 13 June 2025


International Albinism Awareness Day 2025 underscores the urgent need for increased awareness, preventive care, and accessible healthcare for people with albinism. This year’s theme highlights the life-threatening impact of skin cancer among individuals with albinism and reinforces the importance of sun protection, early detection, and timely treatment.

Albinism is a rare, inherited genetic condition that affects the body’s ability to produce melanin, the pigment responsible for the color of our skin, hair, and eyes. People with albinism typically have very light skin and hair, alongside various vision impairments. While it is not contagious and does not affect intelligence, albinism is often misunderstood. This leads to stigmatization, discrimination, and even human rights violations in some regions where harmful myths persist.

Because they have little to no melanin, individuals with albinism are especially vulnerable to sun damage and face a significantly increased risk of developing skin cancer. Addressing this requires more than just clinical intervention—it calls for integrated healthcare policies and inclusive social systems that acknowledge both the medical and socio-political dimensions of the condition.

In recognition of this global observance, we invite you to explore a curated collection of articles and Special Issues from selected MDPI journals, including Biomedicines, Cancers, Children, Diagnostics, Genes, International Journal of Molecular Sciences, Journal of Clinical Medicine and Molecules. These open-access resources provide critical insights into the diagnosis, management, and complications of albinism, and promote cross-disciplinary collaboration between researchers, clinicians, and advocacy groups.

Together, through science, education, and empathy, we can foster a more inclusive world where people with albinism live free from discrimination and with access to the care they deserve.

Can a Portable Flash Visual Evoked Potential (VEP) Device Identify Chiasmal Decussation Anomalies in Albinism?
by Eloise Keeling, Perry Carter, Abdi Malik Musa, Fatima Shawkat, Helena Lee and Jay E. Self
Diagnostics 2025, 15(11), 1395; https://doi.org/10.3390/diagnostics15111395

Common Variants in the TYR Gene with Unclear Pathogenicity as the Cause of Oculocutaneous Albinism in a Cohort of Russian Patients
by Olga Shchagina, Anna Stepanova, Polina Mishakova, Vitaliy Kadyshev, Nina Demina, Ludmila Bessonova, Sofya Ionova, Daria Guseva, Andrey Marakhonov, Rena Zinchenko et al.
Biomedicines 2024, 12(10), 2234; https://doi.org/10.3390/biomedicines12102234

Functional Characterization of Splice Variants in the Diagnosis of Albinism
by Modibo Diallo, Cécile Courdier, Elina Mercier, Angèle Sequeira, Alicia Defay-Stinat, Claudio Plaisant, Shahram Mesdaghi, Daniel Rigden, Sophie Javerzat, Eulalie Lasseaux et al.
Int. J. Mol. Sci. 2024, 25(16), 8657; https://doi.org/10.3390/ijms25168657

Genetic Linkage between CAPN5 and TYR Variants in the Context of Albinism and Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy Absence: A Case Report
by Mirjana Bjeloš, Ana Ćurić, Mladen Bušić, Benedict Rak and Biljana Kuzmanović Elabjer
Int. J. Mol. Sci. 2024, 25(12), 6442; https://doi.org/10.3390/ijms25126442

Missing Heritability in Albinism: Deep Characterization of a Hungarian Albinism Cohort Raises the Possibility of the Digenic Genetic Background of the Disease
by Nikoletta Nagy, Margit Pal, Jozsef Kun, Bence Galik, Peter Urban, Marta Medvecz, Beata Fabos, Alexandra Neller, Aliasgari Abdolreza, Judit Danis, Viktoria Szabo, Zhuo Yang, Stefanie Fenske, Martin Biel, Attila Gyenesei, Eva Adam and Marta Szell
Int. J. Mol. Sci. 2024, 25(2), 1271; https://doi.org/10.3390/ijms25021271

Does Foveal Hypoplasia Affect Emmetropization in Patients with Albinism?
by Line Kessel, Christine Dahlgren Bohnsack Kjølholm and Joaquim Torner Jordana
Children 2023, 10(12), 1910; https://doi.org/10.3390/children10121910

Vision-Related Quality of Life in Danish Patients with Albinism and the Impact of an Updated Optical Rehabilitation
by Kristian Lisbjerg, Joaquim Torner Jordana, Vibeke N. Brandt, Christine Kjølholm and Line Kessel
J. Clin. Med. 2023, 12(17), 5451; https://doi.org/10.3390/jcm12175451

Skin Pigmentation Types, Causes and Treatment—A Review
by Amin Mahmood Thawabteh, Alaa Jibreen, Donia Karaman, Alà Thawabteh and Rafik Karaman
Molecules 2023, 28(12), 4839; https://doi.org/10.3390/molecules28124839

Report of Hermansky–Pudlak Syndrome in Two Families with Novel Variants in HPS3 and HPS4 Genes
by Sadeeda Qaiser Zaman, Muhammad Anas, Gauhar Rehman, Qadeem Khan, Aiman Iftikhar, Mashal Ahmad, Muhammad Owais, Ilyas Ahmad, Osama Yousef Muthaffar, Angham Abdulrhman Abdulkareem et al.
Genes 2023, 14(1), 145; https://doi.org/10.3390/genes14010145

Diagnostic Yield of Genetic Testing for Ocular and Oculocutaneous Albinism in a Diverse United States Pediatric Population
by Kyle S. Chan, Brenda L. Bohnsack, Alexander Ing, Andy Drackley, Valerie Castelluccio, Kevin X. Zhang, Hanta Ralay-Ranaivo and Jennifer L. Rossen
Genes 2023, 14(1), 135; https://doi.org/10.3390/genes14010135

More than Skin Deep—Latest Advances in Congenital and Autoimmune Pigmentation Disorders
Guest Editor: Prof. Dr. Reinhart M. Speeckaert
Submission deadline: 25 August 2025
Melanin Pigmentation: Physiology and Pathology
Guest Editors: Prof. Dr. Shosuke Ito and Prof. Dr. Manickam Sugumaran
Submission deadline: 20 October 2025

Back to TopTop